Aspergillus PCR in serum for the diagnosis, follow-up and prognosis of invasive aspergillosis in neutropenic and nonneutropenic patients

Clinical Microbiology and Infection

Volumn 22, Issue 6, 2016, Pages 562.e1-562.e8

  Imbert, S ^a   Gauthier, L ^a   Joly, I ^a   Brossas, J Y ^c   Uzunov, M ^b   Touafek, F ^a   Brun, S ^a   Mazier, D ^a,c,d   Datry, A ^a   Gay, F ^a,d   Fekkar, A ^a,c,d  

^a Service de Parasitologie Mycologie   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Assistance publique Hôpitaux de Paris   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Aspergillus fumigatus; fungal infection; galactomannan; haematology; solid organ transplant

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; GALACTOMANNAN; VORICONAZOLE; MANNAN;

ADULT; AGED; ANTIFUNGAL THERAPY; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VERY ELDERLY; ASPERGILLUS; BLOOD; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; GENETICS; INVASIVE PULMONARY ASPERGILLOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MOLECULAR DIAGNOSIS; NEOPLASM; POLYMERASE CHAIN REACTION; PROCEDURES; SERUM; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ASPERGILLUS; FEMALE; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MANNANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; NEUTROPENIA; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SERUM; YOUNG ADULT;

EID: 84961912064     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2016.01.027     Document Type: Article

References (22)

1. [1] von Eiff, M., Roos, N., Schulten, R., Hesse, M., Zuhlsdorf, M., van de Loo, J., Pulmonary aspergillosis: early diagnosis improves survival. Respiration 62 (1995), 341–347.
2. [2] Walsh, T.J., Anaissie, E.J., Denning, D.W., Herbrecht, R., Kontoyiannis, D.P., Marr, K.A., et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008), 327–360.
3. [3] De Pauw, B., Walsh, T.J., Donnelly, J.P., Stevens, D.A., Edwards, J.E., Calandra, T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 46 (2008), 1813–1821.
4. [4] Meersseman, W., Lagrou, K., Maertens, J., Wilmer, A., Hermans, G., Vanderschueren, S., et al. Galactomannan in bronchoalveolar lavage fluid: a tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 177 (2008), 27–34.
5. [5] Marty, F.M., Koo, S., Role of (1→3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol 47:Suppl. 1 (2009), S233–S240.
6. [6] Mennink-Kersten, M.A., Warris, A., Verweij, P.E., 1,3-Beta-d-glucan in patients receiving intravenous amoxicillin–clavulanic acid. N Engl J Med 354 (2006), 2834–2835.
7. [7] Sulahian, A., Porcher, R., Bergeron, A., Touratier, S., Raffoux, E., Menotti, J., et al. Use and limits of (1–3)-beta-d-glucan assay (Fungitell), compared to galactomannan determination (platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol 52 (2014), 2328–2333.
8. [8] Fekkar, A., Brun, S., D'Ussel, M., Uzunov, M., Cracco, C., Dhedin, N., et al. Serum cross-reactivity with Aspergillus galactomannan and cryptococcal antigen during fatal disseminated Trichosporon dermatis infection. Clin Infect Dis 49 (2009), 1457–1458.
9. [9] Wheat, L.J., Hackett, E., Durkin, M., Connolly, P., Petraitiene, R., Walsh, T.J., et al. Histoplasmosis-associated cross-reactivity in the biorad platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol 14 (2007), 638–640.
10. [10] Dalle, F., Charles, P.E., Blanc, K., Caillot, D., Chavanet, P., Dromer, F., et al. Cryptococcus neoformans galactoxylomannan contains an epitope(s) that is cross-reactive with Aspergillus galactomannan. J Clin Microbiol 43 (2005), 2929–2931.
11. [11] White, P.L., Wingard, J.R., Bretagne, S., Loffler, J., Patterson, T.F., Slavin, M.A., et al. Aspergillus polymerase chain reaction: systematic review of evidence for clinical use in comparison with antigen testing. Clin Infect Dis 61 (2015), 1293–1303.
12. [12] Prodanovic, H., Cracco, C., Massard, J., Barrault, C., Thabut, D., Duguet, A., et al. Invasive pulmonary aspergillosis in patients with decompensated cirrhosis: case series. BMC Gastroenterol, 7, 2007, 2.
13. [13] Azoulay, E., Lemiale, V., Mokart, D., Pene, F., Kouatchet, A., Perez, P., et al. Acute respiratory distress syndrome in patients with malignancies. Intensive Care Med 40 (2014), 1106–1114.
14. [14] Suarez, F., Lortholary, O., Buland, S., Rubio, M.T., Ghez, D., Mahe, V., et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 46 (2008), 3772–3777.
15. [15] Challier, S., Boyer, S., Abachin, E., Berche, P., Development of a serum-based TaqMan real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 42 (2004), 844–846.
16. [16] Mengoli, C., Cruciani, M., Barnes, R.A., Loeffler, J., Donnelly, J.P., Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. Lancet Infect Dis 9 (2009), 89–96.
17. [17] Arvanitis, M., Ziakas, P.D., Zacharioudakis, I.M., Zervou, F.N., Caliendo, A.M., Mylonakis, E., PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol 52 (2014), 3731–3742.
18. [18] Arvanitis, M., Anagnostou, T., Mylonakis, E., Galactomannan and polymerase chain reaction–based screening for invasive aspergillosis among high-risk hematology patients: a diagnostic meta-analysis. Clin Infect Dis 61 (2015), 1263–1272.
19. [19] Koo, S., Bryar, J.M., Baden, L.R., Marty, F.M., Prognostic features of galactomannan antigenemia in galactomannan-positive invasive aspergillosis. J Clin Microbiol 48 (2010), 1255–1260.
20. [20] Bergeron, A., Porcher, R., Menotti, J., Poirot, J.L., Chagnon, K., Vekhoff, A., et al. Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients. J Clin Microbiol 50 (2012), 823–830.
21. [21] White, P.L., Barnes, R.A., Springer, J., Klingspor, L., Cuenca-Estrella, M., Morton, C.O., et al. Clinical performance of Aspergillus PCR when testing serum and plasma—a study by the European Aspergillus PCR Initiative. J Clin Microbiol 53 (2015), 2832–2837.
22. [22] Steinbach, W.J., Marr, K.A., Anaissie, E.J., Azie, N., Quan, S.P., Meier-Kriesche, H.U., et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65 (2012), 453–464.